Literature DB >> 22752545

Selectivity and activation of dopamine D3R from molecular dynamics.

Zhiwei Feng1, Tingjun Hou, Youyong Li.   

Abstract

D(3) receptor, a member of dopamine (DA) D(2)-like receptor family, which belongs to class A of G-protein coupled receptors (GPCRs), has been reported to play a critical role in neuropsychiatric disorders. Recently, the crystal structure of human dopamine D3 receptor was reported, which facilitates structure-based drug discovery of D3R significantly. We dock D3R-selective compounds into the crystal structure of D3R and homology structure of D2R. Then we perform 20 ns molecular dynamics (MD) of the receptor with selective compounds bound in explicit lipid and water. Our docking and MD results indicate the important residues related to the selectivity of D3R. Specifically, residue Thr(7.39) in D3R may contribute to the high selectivity of R-22 with D3R. Meanwhile, the 4-carbon linker and phenylpiperazine of R-22 improve the binding affinity and the selectivity with D3R. We also dock the agonists, including dopamine, into D3R and perform MD. Our molecular dynamics results of D3R with agonist bound show strong conformational changes from TM5, TM6, and TM7, outward movement of intracellular part of TM6, fluctuation of "ionic lock" motif and conformational change of Tyr(7.53), which is consistent with recent crystal structures of active GPCRs and illustrates the dynamical process during activation. Our results reveal the mechanism of selectivity and activation for D3R, which is important for developing high selective antagonists and agonists for D3R.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752545     DOI: 10.1007/s00894-012-1509-x

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  57 in total

1.  The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered.

Authors:  P M Beardsley; P Sokoloff; R L Balster; J C Schwartz
Journal:  Behav Pharmacol       Date:  2001-02       Impact factor: 2.293

2.  Studies on the interactions between β2 adrenergic receptor and Gs protein by molecular dynamics simulations.

Authors:  Zhiwei Feng; Tingjun Hou; Youyong Li
Journal:  J Chem Inf Model       Date:  2012-03-29       Impact factor: 4.956

3.  Saturation with cholesterol increases vertical order and smoothes the surface of the phosphatidylcholine bilayer: a molecular simulation study.

Authors:  Elżbieta Plesnar; Witold K Subczynski; Marta Pasenkiewicz-Gierula
Journal:  Biochim Biophys Acta       Date:  2011-10-29

4.  Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands.

Authors:  Raquel Ortega; Enrique Raviña; Christian F Masaguer; Filipe Areias; José Brea; María I Loza; Laura López; Jana Selent; Manuel Pastor; Ferran Sanz
Journal:  Bioorg Med Chem Lett       Date:  2009-01-27       Impact factor: 2.823

5.  The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats.

Authors:  Zheng-Xiong Xi; Amy Hauck Newman; Jeremy G Gilbert; Arlene C Pak; Xiao-Qing Peng; Charles R Ashby; Leah Gitajn; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2005-10-05       Impact factor: 7.853

6.  Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.

Authors:  Peng Zhang; George Cyriac; Theresa Kopajtic; Yongfang Zhao; Jonathan A Javitch; Jonathan L Katz; Amy Hauck Newman
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

Review 7.  Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates.

Authors:  Stefan Löber; Harald Hübner; Nuska Tschammer; Peter Gmeiner
Journal:  Trends Pharmacol Sci       Date:  2011-01-12       Impact factor: 14.819

8.  The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.

Authors:  Elena Silvano; Mark J Millan; Clotilde Mannoury la Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

9.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

10.  The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2007-11-06       Impact factor: 4.530

View more
  8 in total

1.  Structural signatures of DRD4 mutants revealed using molecular dynamics simulations: Implications for drug targeting.

Authors:  Nidhi Jatana; Lipi Thukral; N Latha
Journal:  J Mol Model       Date:  2015-12-17       Impact factor: 1.810

Review 2.  Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.

Authors:  Zhiwei Feng; Guanxing Hu; Shifan Ma; Xiang-Qun Xie
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

3.  Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family.

Authors:  Zhiwei Feng; Shifan Ma; Guanxing Hu; Xiang-Qun Xie
Journal:  AAPS J       Date:  2015-03-12       Impact factor: 4.009

4.  Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.

Authors:  Xiaomeng Xu; Shifan Ma; Zhiwei Feng; Guanxing Hu; Lirong Wang; Xiang-Qun Xie
Journal:  J Mol Graph Model       Date:  2016-08-08       Impact factor: 2.518

5.  α2A- and α2C-Adrenoceptors as Potential Targets for Dopamine and Dopamine Receptor Ligands.

Authors:  Marta Sánchez-Soto; Verònica Casadó-Anguera; Hideaki Yano; Brian Joseph Bender; Ning-Sheng Cai; Estefanía Moreno; Enric I Canela; Antoni Cortés; Jens Meiler; Vicent Casadó; Sergi Ferré
Journal:  Mol Neurobiol       Date:  2018-03-18       Impact factor: 5.590

6.  Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.

Authors:  Jianping Hu; Zhiwei Feng; Shifan Ma; Yu Zhang; Qin Tong; Mohammed Hamed Alqarni; Xiaojun Gou; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2016-05-26       Impact factor: 4.956

7.  Structural and Functional Effect of an Oscillating Electric Field on the Dopamine-D3 Receptor: A Molecular Dynamics Simulation Study.

Authors:  Zohreh Fallah; Yousef Jamali; Hashem Rafii-Tabar
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

8.  Discovery of CNS-Like D3R-Selective Antagonists Using 3D Pharmacophore Guided Virtual Screening.

Authors:  June Hyeong Lee; Sung Jin Cho; Mi-Hyun Kim
Journal:  Molecules       Date:  2018-09-25       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.